ALLO
Price
$1.13
Change
-$0.05 (-4.24%)
Updated
Sep 17 closing price
Capitalization
261.82M
42 days until earnings call
CRSP
Price
$59.07
Change
-$2.12 (-3.46%)
Updated
Sep 17, 04:59 PM (EDT)
Capitalization
5.57B
41 days until earnings call
Interact to see
Advertisement

ALLO vs CRSP

Header iconALLO vs CRSP Comparison
Open Charts ALLO vs CRSPBanner chart's image
Allogene Therapeutics
Price$1.13
Change-$0.05 (-4.24%)
Volume$3.18M
Capitalization261.82M
CRISPR Therapeutics AG
Price$59.07
Change-$2.12 (-3.46%)
Volume$56.54K
Capitalization5.57B
ALLO vs CRSP Comparison Chart in %
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. CRSP commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a StrongBuy and CRSP is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (ALLO: $1.13 vs. CRSP: $59.07)
Brand notoriety: ALLO and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 77% vs. CRSP: 100%
Market capitalization -- ALLO: $261.82M vs. CRSP: $5.57B
ALLO [@Biotechnology] is valued at $261.82M. CRSP’s [@Biotechnology] market capitalization is $5.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, CRSP is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 3 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 3 bullish, 3 bearish.
  • CRSP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than CRSP.

Price Growth

ALLO (@Biotechnology) experienced а +1.80% price change this week, while CRSP (@Biotechnology) price change was +14.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +6.08%, and the average quarterly price growth was +34.58%.

Reported Earning Dates

ALLO is expected to report earnings on Oct 30, 2025.

CRSP is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.57B) has a higher market cap than ALLO($262M). CRSP YTD gains are higher at: 50.076 vs. ALLO (-46.948). ALLO has higher annual earnings (EBITDA): -223.22M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. ALLO (273M). ALLO has less debt than CRSP: ALLO (79.2M) vs CRSP (215M). CRSP has higher revenues than ALLO: CRSP (35M) vs ALLO (0).
ALLOCRSPALLO / CRSP
Capitalization262M5.57B5%
EBITDA-223.22M-533.5M42%
Gain YTD-46.94850.076-94%
P/E RatioN/AN/A-
Revenue035M-
Total Cash273M1.72B16%
Total Debt79.2M215M37%
FUNDAMENTALS RATINGS
ALLO vs CRSP: Fundamental Ratings
ALLO
CRSP
OUTLOOK RATING
1..100
126
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
6441
P/E GROWTH RATING
1..100
10077
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (64) in the Biotechnology industry is somewhat better than the same rating for ALLO (97). This means that CRSP’s stock grew somewhat faster than ALLO’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that CRSP’s stock grew similarly to ALLO’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as ALLO (98). This means that CRSP’s stock grew similarly to ALLO’s over the last 12 months.

CRSP's Price Growth Rating (41) in the Biotechnology industry is in the same range as ALLO (64). This means that CRSP’s stock grew similarly to ALLO’s over the last 12 months.

CRSP's P/E Growth Rating (77) in the Biotechnology industry is in the same range as ALLO (100). This means that CRSP’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOCRSP
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 15 days ago
89%
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JVCZY46.62N/A
N/A
JVCKenwood Corp.
MNODF13.53N/A
N/A
Mondi Plc.
IXAQF12.01N/A
N/A
IX Acquisition Corp.
CLCFF0.03N/A
-2.16%
Christina Lake Cannabis Corp.
DSKYF24.12-1.48
-5.78%
Daiichi Sankyo Co., Ltd.